Abstract:BACKGROUND:Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the oldest known and most dangerous diseases. Although the spread of TB was controlled in the early 20th century using antibiotics and vaccines, TB has again become a threat because of increased drug resistance. There is still a lack of effective treatment regimens for a person who is already infected with multidrug-resistant Mtb (MDR-Mtb) or extensively drug-resistant Mtb (XDRMtb). In the past decades, many research groups have explored the drug resistance profiles of Mtb based on sequence data by GWAS, which identified some mutations that were significantly linked with drug resistance, and attempted to explain the resistance mechanisms. However, they mainly focused on several significant mutations in drug targets (e.g. rpoB, katG). Some genes which are potentially associated with drug resistance may be overlooked by the GWAS analysis.OBJECTIVE:In this article, our motivation is to detect potential drug resistance genes of Mtb using a heat diffusion model.METHODS:All sequencing data, which contained 127 samples of Mtb, i.e. 34 ethambutol-, 65 isoniazid-, 53 rifampicin- and 45 streptomycin-resistant strains. The raw sequence data were preprocessed using Trimmomatic software and aligned to the Mtb H37Rv reference genome using Bowtie2. From the resulting alignments, SAMtools and VarScan were used to filter sequences and call SNPs. The GWAS was performed by the PLINK package to obtain the significant SNPs, which were mapped to genes. The P-values of genes calculated by GWAS were transferred into a heat vector. The heat vector and the Mtb protein-protein interactions (PPI) derived from the STRING database were inputted into the heat diffusion model to obtain significant subnetworks by HotNet2. Finally, the most significant (P < 0.05) subnetworks associated with different phenotypes were obtained. To verify the change of binding energy between the drug and target before and after mutation, the method of molecular dynamics simulation was performed using the AMBER software.RESULTS:We identified significant subnetworks in rifampicin-resistant samples. Excitingly, we found rpoB and rpoC, which are drug targets of rifampicin. From the protein structure of rpoB, the mutation location was extremely close to the drug binding site, with a distance of only 3.97 Å. Molecular dynamics simulation revealed that the binding energy of rpoB and rifampicin decreased after D435V mutation. To a large extent, this mutation can influence the affinity of drug-target binding. In addition, topA and pyrG were reported to be linked with drug resistance, and might be new TB drug targets. Other genes that have not yet been reported are worth further study.CONCLUSION:Using a heat diffusion model in combination with GWAS results and protein-protein interactions, the significantly mutated subnetworks in rifampicin-resistant samples were found. The subnetwork not only contained the known targets of rifampicin (rpoB, rpoC), but also included topA and pyrG, which are potentially associated with drug resistance. Together, these results offer deeper insights into drug resistance of Mtb, and provides potential drug targets for finding new antituberculosis drugs.

Compensatory evolution in NusG improves fitness of drug-resistant M. tuberculosis

Mycobacterium Tuberculosis Carrying a Rifampicin Drug Resistance Mutation Reprograms Macrophage Metabolism Through Cell Wall Lipid Changes

Transcriptional Approach for Decoding the Mechanism of Rpoc Compensatory Mutations for the Fitness Cost in Rifampicin-Resistant Mycobacterium Tuberculosis

Compensatory mutations are associated with increased in vitro growth in resistant clinical samples of Mycobacterium tuberculosis

Tuberculosis treatment failure associated with evolution of antibiotic resilience

Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis

Identification of gene targets that potentiate the action of rifampicin on Mycobacterium bovis BCG

Large-scale statistical analysis of Mycobacterium tuberculosis genome sequences identifies compensatory mutations associated with multi-drug resistance

Fitness cost and compensatory evolution of drug-resistant Mycobacterium tuberculosis

Novel and reported compensatory mutations in rpoABC genes found in drug resistant tuberculosis outbreaks

Selective Pressure by Rifampicin Modulates Mutation Rates and Evolutionary Trajectories of Mycobacterial Genomes

Mutations in Dnaa and a Cryptic Interaction Site Increase Drug Resistance in Mycobacterium Tuberculosis.

Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development

Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment

High-throughput Mutagenesis and Screening Approach for the Identification of Drug-Resistant Mutations in the Rifampicin Resistance-Determining Region of Mycobacteria

Using a Heat Diffusion Model to Detect Potential Drug Resistance Genes of Mycobacterium Tuberculosis.

In Vivo Evolution of Drug-Resistant Mycobacterium Tuberculosis in Patients During Long-Term Treatment

Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons

Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India

Mycobacterium Tuberculosis Functional Genetic Diversity, Altered Drug Sensitivity, and Precision Medicine.

Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis